Pharmaceuticals

• 

  10/2/2024

  **Melanoma Data Release: Proof-of-Concept for Radiotherapy**

• 10/2/2024

  **AbbVie: $200 Peak Rating Downgraded**

• 10/2/2024

  **AbbVie’s Skyrizi and Rinvoq: Worth the Premium**

• 10/1/2024

  **IBD Targeting: Unlocking Differentiation with Advanced Half-Life Tech**

• 10/1/2024

  **Apellis Pharmaceuticals: Navigating CHMP Setback**

• 10/1/2024

  **Maximize Your Returns with Pfizer**

• 9/30/2024

  **Pfizer: Buy for Oncology Growth**

• 9/30/2024

  **Inovio Pharmaceuticals: Weathering the Storm**

• 9/30/2024

  **Eli Lilly’s Ebglyss Takes on Dupixent in Atopic Dermatitis**

• 9/30/2024

  **Travere Therapeutics: Overcoming Challenges with Filspari’s Potential**